{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:26:45Z","timestamp":1763630805518,"version":"3.45.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Beijing Municipal","award":["7254325"],"award-info":[{"award-number":["7254325"]}]},{"name":"the Capital\u2019s Funds for Health Improvement and Research","award":["2022-2Z-20216"],"award-info":[{"award-number":["2022-2Z-20216"]}]},{"name":"the National Key Research and Development Program of China","award":["2024YFF1207000"],"award-info":[{"award-number":["2024YFF1207000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12053-4","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:22:05Z","timestamp":1763630525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, immunogenicity, persistence and dose evaluation of the CS-2034 mRNA COVID-19 vaccine: a phase II randomized controlled trial in healthy Chinese adults"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhili","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbo","family":"Gou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruihua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"12053_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"X Enyue Fang","year":"2022","unstructured":"Enyue Fang X, Liu M, Li Z, Zhang L, Song B, Zhu, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7:94.","journal-title":"Signal Transduct Target Ther"},{"key":"12053_CR2","first-page":"50","volume":"10","author":"A Ouranidis","year":"2021","unstructured":"Ouranidis A, Vavilis T, Mandala E, Davidopoulou C, Stamoula E, Markopoulou CK, et al. MRNA therapeutic modalities design, formulation and manufacturing under pharma 4.0 principles. Biomed. 2021;10:50.","journal-title":"Biomed"},{"key":"12053_CR3","doi-asserted-by":"publisher","first-page":"108162","DOI":"10.1016\/j.intimp.2021.108162","volume":"100","author":"P Ghasemiyeh","year":"2021","unstructured":"Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin A. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. Int Immunopharmacol. 2021;100:108162.","journal-title":"Int Immunopharmacol"},{"key":"12053_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1055\/a-2531-1211","volume":"46","author":"A Trilla","year":"2025","unstructured":"Trilla A, Trilla G, Aldea M, Vilella A. What is next for COVID-19 vaccination? Semin Respir Crit Care Med. 2025;46:82\u201394.","journal-title":"Semin Respir Crit Care Med"},{"key":"12053_CR5","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1001\/jama.2025.5646","volume":"333","author":"KR Amanda","year":"2025","unstructured":"Amanda KR, Spergel I, Wu W, Deng J, Cardona K, Johnson I, Espinosa-Fernandez, et al. Immunogenicity and safety of influenza and COVID-19 multicomponent vaccine in Adults\u2009\u2265\u200950 years: A randomized clinical trial. JAMA. 2025;333:1977\u201387.","journal-title":"JAMA"},{"key":"12053_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"R Lindsey","year":"2021","unstructured":"Lindsey R, Baden, Hana ME, Sahly B, Essink K, Kotloff S, Frey R, Novak, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403\u201316.","journal-title":"N Engl J Med"},{"key":"12053_CR7","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"P Fernando","year":"2020","unstructured":"Fernando P, Polack SJ, Thomas N, Kitchin J, Absalon A, Gurtman S, Lockhart, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"12053_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jinf.2023.10.012","volume":"87","author":"J Zhili Jin","year":"2023","unstructured":"Zhili Jin J, Wu Y, Wang T, Huang K, Zhao J, Liu, et al. Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter phase I clinical trial in healthy Chinese adults. J Infect. 2023;87:556\u201370.","journal-title":"J Infect"},{"key":"12053_CR9","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"A Lisa","year":"2020","unstructured":"Lisa A, Jackson EJ, Anderson, Nadine G, Rouphael PC, Roberts M, Makhene, Rhea N, Coler, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383:1920\u201331.","journal-title":"N Engl J Med"},{"key":"12053_CR10","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"E Edward","year":"2020","unstructured":"Edward E, Walsh RW, Frenck AR Jr, Falsey N, Kitchin J, Absalon A, Gurtman, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439\u201350.","journal-title":"N Engl J Med"},{"key":"12053_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"A Ugur Sahin","year":"2020","unstructured":"Ugur Sahin A, Muik E, Derhovanessian I, Vogler LM, Kranz M, Vormehr, et al. COVID- 19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594\u20139.","journal-title":"Nature"},{"key":"12053_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"J Mark","year":"2020","unstructured":"Mark J, Mulligan KE, Lyke N, Kitchin J, Absalon A, Gurtman S, Lockhart, et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589\u201393.","journal-title":"Nature"},{"key":"12053_CR13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.medj.2022.04.013","volume":"3","author":"Y Yohei Seki","year":"2022","unstructured":"Yohei Seki Y, Yoshihara K, Nojima H, Momose S, Fukushi S, Moriyama, et al. Safety and immunogenicity of the Pfizer\/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. Med. 2022;3:406\u201321.","journal-title":"Med"},{"key":"12053_CR14","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/j.immuni.2021.06.015","volume":"54","author":"Y Saya Moriyama","year":"2021","unstructured":"Saya Moriyama Y, Adachi T, Sato K, Tonouchi L, Fukushi SS, et al. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to Circulating SARS-CoV-2 variants. Immunity. 2021;54:1841\u201352.","journal-title":"Immunity"},{"key":"12053_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/22221751.2021.1902245","volume":"10","author":"Q He","year":"2021","unstructured":"He Q, Mao Q, An C, Zhang J, Gao F, Bian L, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10:629\u201337.","journal-title":"Emerg Microbes Infect"},{"key":"12053_CR16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1473-3099(23)00199-8","volume":"23","author":"J-D Wu","year":"2023","unstructured":"Wu J-D, Li J-X, Liu J, Wang H-M, Zhou G-H, Li J, et al. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged\u2009\u2265\u200918 years: a randomised, double- blind, phase 2b trial. Lancet Infect Dis. 2023;23:1020\u201330.","journal-title":"Lancet Infect Dis"},{"key":"12053_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bbrc.2020.10.012","volume":"538","author":"M Yuan","year":"2021","unstructured":"Yuan M, Liu H, Nicholas C, Wu, Ian A, Wilson. Recognition of the SARSCoV-2 receptor binding domain by neutralizing antibodies. Biochem Biophys Res Commun. 2021;538:192\u2013203.","journal-title":"Biochem Biophys Res Commun"},{"key":"12053_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4049\/jimmunol.1801149","volume":"202","author":"A Zhang","year":"2019","unstructured":"Zhang A, Hannah D, Stacey CE, Mullarkey, Matthew S, Miller. Original antigenic sin: how first exposure shapes lifelong anti\u2013influenza virus immune responses. J Immunol. 2019;202:335\u201340.","journal-title":"J Immunol"},{"key":"12053_CR19","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","volume":"27","author":"A Choi","year":"2021","unstructured":"Choi A, Koch M, Wu K, Chu L, Ma LZ, Hill A, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021;27:2025\u201331.","journal-title":"Nat Med"},{"key":"12053_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","volume":"185","author":"CA Katharina R\u00f6ltgen, Sandra","year":"2022","unstructured":"Katharina R\u00f6ltgen, Sandra CA, Nielsen O, Silva SF, Younes M, Zaslavsky C, Costales, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185:1025\u201340.","journal-title":"Cell"},{"key":"12053_CR21","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.4049\/jimmunol.2100637","volume":"207","author":"S Sandhya Bansal","year":"2021","unstructured":"Sandhya Bansal S, Perincheri T, Fleming C, Poulson B, Tiffany, Ross M, Bremner, et al. Cutting edge: Circulating exosomes with COVID Spike protein are induced by BNT162b2 (Pfizer-BioNTech) vaccination prior to development of antibodies: a NoNvel mechanism for immune activation by mRNA vaccines. J Immunol. 2021;207:2405\u201310.","journal-title":"J Immunol"},{"key":"12053_CR22","first-page":"141","volume":"27","author":"J Aram","year":"2023","unstructured":"Aram J, Krauson F, Victoria C, Casimero Z, Siddiquee JR, Stone. Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. NPJ Vaccines. 2023;27:141.","journal-title":"NPJ Vaccines"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12053-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:22:07Z","timestamp":1763630527000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-12053-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12053"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12053-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All versions of the clinical trial protocol and related documents underwent review and approval by the Institutional Review Board of Beijing Friendship Hospital, Capital Medical University (2022-P1-drug 030\u2009\u2212\u200903). The study was performed in accordance with the ethical standards as laid down in the Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors Jian Liu, Tao Zhu, Haitao Huang, Jin Li, Haomeng Wang, Jinbo Gou were employed by the CanSino (Shanghai) Biotechnologies Co., Ltd., CanSino (Shanghai) Biological Research Co., Ltd. and CanSino Biologics Inc (Tianjin). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from CanSino (Shanghai) Biotechnologies Co., Ltd. and CanSino Biologics Inc (Tianjin). The funder had the following involvement in the study: study design and the decision to submit it for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1625"}}